Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population.
Eur Rev Med Pharmacol Sci
; 26(3 Suppl): 87-93, 2022 12.
Article
in English
| MEDLINE | ID: covidwho-2205444
ABSTRACT
OBJECTIVE:
COVID-19 toes represent the main dermatological COVID-19 cutaneous manifestation in pediatric patients. Its diagnosis exposes the whole family to social stigma and this aspect was not previously evaluated. PATIENTS ANDMETHODS:
This was a multicenter, case-control, observational study that compared the family impact of COVID-19 toes vs. psoriasis (PsO). We enrolled 46 pediatric patients (23 with psoriasis and 23 with COVID-19 toes, age and gender matched) and their parents/caregivers that had to fill the Dermatitis Family Impact (DFI) questionnaire.RESULTS:
DFI index did not differ significantly between both subgroups (p=0.48), and in psoriatic patients did not correlate with both Psoriasis Area Severity Index (PASI) (p=0.59) and itch-VAS (p=0.16).CONCLUSIONS:
COVID-19 toes, a transitory dermatosis, exerted a similar impact/perturbation on family dynamics than PsO, a well-known stigmatizing, chronic inflammatory dermatosis.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Psoriasis
/
Skin Diseases
/
Chilblains
/
Dermatitis
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2022
Document Type:
Article
Affiliation country:
Eurrev_202212_30798
Similar
MEDLINE
...
LILACS
LIS